I know Eli Lilly is the most important company when it comes to obesity drugs, but now that Novo Nordisk has launched oral Wegovy, a drug that, according to Ro Health's CEO, is generating huge demand now that Eli Lilly's Orforglipron has not yet been launched, do you think it's a good time to buy NVO at 15 times its value?